Ono Pharmaceutical (OTCMKTS:OPHLF) Sees Strong Trading Volume - Here's What Happened

Key Points

• Ono Pharmaceutical experienced a significant increase in trading volume, with 19,393 shares traded, marking a 177% surge from the previous session.
• The company's latest earnings report revealed an EPS of $0.26, which was below the consensus estimate of $0.34, but revenue for the quarter exceeded expectations at $886.27 million.
• Ono has a solid balance sheet, demonstrated by its current ratio of 2.99 and debt-to-equity ratio of 0.13, alongside a market capitalization of $5.66 billion.

Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report) shares saw strong trading volume on Monday . 19,393 shares were traded during mid-day trading, an increase of 177% from the previous session's volume of 7,003 shares.The stock last traded at $12.05 and had previously closed at $12.22.

Ono Pharmaceutical Price Performance

The company has a current ratio of 2.99, a quick ratio of 2.44 and a debt-to-equity ratio of 0.13. The stock has a fifty day simple moving average of $11.08 and a 200-day simple moving average of $10.93. The company has a market capitalization of $5.66 billion, a PE ratio of 19.44 and a beta of 0.19.

Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.34 by ($0.08). Ono Pharmaceutical had a return on equity of 5.47% and a net margin of 8.75%.The business had revenue of $886.27 million during the quarter, compared to analyst estimates of $827.29 million.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.